What’s Keytruda, why is it a big deal in India’s cancer fight
360° Perspective Analysis
Deep-dive into Geography, Polity, Economy, History, Environment & Social dimensions — AI-powered, on-demand
Context
Merck's Keytruda, a leading cancer immunotherapy drug, is seeing a surge in counterfeit markets in India due to its prohibitive cost of over Rs 3 lakh per month. Although the Indian government previously exempted it from basic customs duty to improve affordability, the overarching challenge of rising cancer incidence and patent monopolies underscores the need for indigenous healthcare solutions.
UPSC Perspectives
Science & Technology Lens (Biotechnology & Immunotherapy)
Immunotherapy represents a paradigm shift in oncology by training the body's own immune system to target cancer, unlike traditional chemotherapy which directly kills both cancerous and healthy cells indiscriminately. Keytruda is a monoclonal antibody that functions as a checkpoint inhibitor; it blocks the PD-1 pathway, effectively removing the 'brakes' on T-cells so they can naturally identify and attack tumors. Another advanced frontier is CAR-T cell therapy, which involves extracting a patient's T-cells, genetically engineering them in a lab to recognize specific cancer cells, and re-infusing them. To democratize access to these cutting-edge treatments, incubated to develop , India's first indigenous CAR-T therapy, which drastically reduces treatment costs. UPSC aspirants should clearly understand these distinct biotech applications, as prelims frequently target the specific mechanisms of emerging medical technologies.
Public Health & Governance Lens
India is facing a rising non-communicable disease burden, with a recent study indicating that cancer incidence has steadily risen to 107.2 per 100,000 population. As advanced biologic therapies become standard care globally, their prohibitive costs create massive healthcare inequities within developing nations. Patients often rely on government welfare networks like the or restrictive corporate patient access programs to afford treatment. However, the exorbitant pricing has spawned a dangerous counterfeit market, exposing critical regulatory gaps in hospital-level pharmacy supply chains. The is legally responsible for ensuring drug safety and efficacy, but these systemic breaches require much stricter oversight and track-and-trace mechanisms. Effective healthcare governance must balance pharmaceutical innovation with affordable access, ideally expanding advanced cancer care coverage under umbrellas like to shield citizens from catastrophic out-of-pocket health expenditures.
Economic & Intellectual Property Lens
The prohibitive cost of cutting-edge biopharmaceuticals is primarily driven by patent monopolies protected under international trade frameworks, which temporarily prevent cheaper generic competition. Keytruda's global patent, held by Merck, is set to expire in 2028, after which the market will see an influx of much cheaper biosimilars (the highly similar biologic equivalent of generic drugs). To provide immediate financial relief to patients in the interim, the Union Government fully exempted Keytruda and several rare disease drugs from basic customs duty in early 2023. This crucial fiscal intervention lowers the landed cost of imported life-saving medicines. For UPSC preparation, the fundamental tension between Intellectual Property Rights (IPR) and public health equity remains a classic GS-3 theme. The eventual entry of domestic biosimilars will not only reduce out-of-pocket expenditure for patients but also significantly boost India's domestic biopharmaceutical manufacturing sector.